There is a dire need to identify biomarkers of sensitivity, response, and resistance that should be individualized for each tumor and patient to optimize the therapeutic window of these drugs, which requires a deeper understanding of AKT’s perplexing biology. Here, AKT1 is linked to neoplasm.